The need to exploit both marketing and R&D assets, coupled with the expiration of patent coverage has fuelled change and reshaped the pharmaceutical brandscape. Increasingly stringent standards set by regulatory authorities mean that, now more than ever, meaningful distinction between pharmaceutical brands is of paramount importance.
